EFFECTS OF CAPTOPRIL ON SYMPATHETIC ACTIVITY, LIPID AND CARBOHYDRATE-METABOLISM IN A MODEL OF OBESITY-INDUCED HYPERTENSION IN DOGS

被引:27
作者
ROBLES, RG
VILLA, E
SANTIRSO, R
MARTINEZ, J
RUILOPE, LM
CUESTA, C
SANCHO, JM
机构
[1] From the Endocrinology and Pathology Departments, Hospital Ramón y Cajal
[2] Nephrology Department, Hospital 12 de Octubre, Madrid
[3] Servicio de Endocrinologia, Hospital Ramón y Cajal, Madrid, 28034, Carr. Colmenar Km 9
关键词
CAPTOPRIL; OBESITY; HYPERTENSION; SYMPATHETIC ACTIVITY; LIPID METABOLISM;
D O I
10.1093/ajh/6.12.1009
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Ten age-matched beagle dogs were kept on a high-fat diet and followed for 12 weeks. During this period the animals were divided into two groups (n=5), either with or without oral captopril treatment. Dogs were tested periodically for biochemical and clinical parameters, and at the end of the study animals were killed and thoracic aorta samples were obtained for histologic evaluation. From the third week, the captopril group presented significantly lower values of mean arterial pressure, plasma norepinephrine, and fasting glucose and cholesterol levels than those attained in the nontreated group. Furthermore, aorta samples from untreated animals showed profuse staining for fat content at the intima and adventitia layers, while this reaction was restricted to the outer layer in treated dogs. These data suggest that the beneficial effects of captopril therapy in this obesity-induced hypertension model could be based on blood pressure control, together with reduction of serum glucose, cholesterol, and sympathetic activity levels. In addition, captopril treatment could play a role in the retardation of the early stages of vascular atherogenetic lesion.
引用
收藏
页码:1009 / 1015
页数:7
相关论文
共 29 条
  • [1] Chiang B.N., Perlman L.V., Epstein F.H., Overweight and hypertension: A review, Circulation, 39, pp. 403-421, (1969)
  • [2] Rocchini A.P., The influence of obesity in hypertension, News Physiol Sci, 5, pp. 245-249, (1990)
  • [3] Ferrannini E., Metabolic abnormalities of hyperten¬ sion. A lesson of complexity, Hypertension, 18, pp. 636-639, (1991)
  • [4] Frohlich E.D., Obesity hypertension: Converting en¬ zyme inhibitors and calcium antagonists, Hyperten¬ Sion, 19, pp. 1119-1123, (1992)
  • [5] Salmon M.G., Lahera V., Romero J.C., Role of prostaglan¬ dins and endothelium-derived relaxin factor on the renal response to acetylcholine, Am J Physiol, 260, pp. F145-F149, (1991)
  • [6] Opgenorth T.J., Granger J.P., Chakravarty A., Et al., Effect of intrarenal angiotensin-II infusion on the renal es¬ cape from mineralocorticoid, Am J Physiol, 145, pp. F813-F818, (1985)
  • [7] Villa E., Martinez J., Ruilope L.M., Et al., Cicaprost, a prostacyclin analog, protects renal function in unine- phrectomized dogs in the absence of changes in blood pressure, Am J Hypertens, 6, pp. 253-257, (1993)
  • [8] Luna L.G., Methods for fats and lipids, Manual of Histologic Staining Methods of the Armed Forces, pp. 140-141, (1968)
  • [9] Goldstein D.S., Feuerstein G., Izzo J.L., Et al., Validity and reliability of liquid chromatography with electro¬ chemical detection for measuring plasma levels of nor¬ epinephrine and epinephrine in man, Life Sci, 28, pp. 467-475, (1981)
  • [10] Rocchini A.P., Cardiovascular regulation in obesity- induced hypertension, Hypertension, 19, pp. 156-160, (1992)